Planning cancer control in Latin America and the Caribbean

PE Goss, BL Lee, T Badovinac-Crnjevic… - The lancet …, 2013 - thelancet.com
Non-communicable diseases, including cancer, are overtaking infectious disease as the
leading health-care threat in middle-income and low-income countries. Latin American and …

The blue palate—A case series of imatinib-related oral pigmentation and literature review

CC Donnell, RL Walton, M Carrozzo - Oral Surgery, Oral Medicine, Oral …, 2021 - Elsevier
Pigmented oral mucosal lesions are diverse, and differential diagnosis can range from
benign conditions such as oral melanotic macule to malignancies such as oral malignant …

[HTML][HTML] Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

N Pemmaraju, H Kantarjian, J Shan, E Jabbour… - …, 2012 - ncbi.nlm.nih.gov
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia
treated with upfront tyrosine kinase inhibitor therapy - PMC Back to Top Skip to main content NIH …

The treatment of CML at an environment with limited resources

D Gómez-Almaguer, OG Cantú-Rodríguez… - …, 2016 - Taylor & Francis
Objectives: This article reviews clinical experiences in the treatment of chronic myeloid
leukemia (CML) in an environment of limited resources. Methods: We reviewed recent …

Trends in cancer mortality in Mexico, 1981–2007

C Bosetti, T Rodríguez, L Chatenoud… - European Journal of …, 2011 - journals.lww.com
The objective of this study was to provide information on recent trends in cancer mortality in
Mexico. We analyzed data provided by the World Health Organization, using joinpoint …

[PDF][PDF] La planificación del control del cáncer en América Latina y el Caribe

G De Massachusetts, B Israel, E UU… - Lancet …, 2013 - paliativossinfronteras.org
Las enfermedades no transmisibles, incluido el cáncer, están sobrepasando a las
enfermedades infecciosas como la principal amenaza de salud en los países de ingresos …

Treatment patterns and deep molecular response in chronic phase–chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country …

J Cortes, L Huynh, E Mendelson, P Brandt… - Leukemia & …, 2020 - Taylor & Francis
Abstract Achievement of MR4. 5 (BCR-ABL1≤ 0.0032% on international scale) is an
important goal of tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid …

Recovering from chronic myeloid leukemia: the patients' perspective seen through the lens of narrative medicine

G Graffigna, I Cecchini, M Breccia, E Capochiani… - Quality of Life …, 2017 - Springer
Purpose The main objective of this study is to gain a deeper understanding of how patients
suffering from chronic myeloid leukemia (CML) cope with their illness. The study aims to …

Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute–Mexico, from 2000 to 2016

J Ylescas‐Soria, AH de la Torre‐Lujan… - Cancer …, 2019 - Wiley Online Library
To determine potential predictors of long‐term survival in a large set of Hispanic (Mexican)
patients with chronic myeloid leukemia (CML) treated with imatinib. We conducted an …

Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor

N Hamerschlak, C De Souza, AL Cornacchioni… - Supportive care in …, 2014 - Springer
Purpose The purpose of this study was to evaluate the quality of life (QOL) of patients
receiving treatment by the public health system in Brazil for chronic myeloid leukemia (CML) …